Three Defense Bills, One Sponsor, One Day: a House Push to Scrub Foreign Tech From Defense Systems

One sponsor, three referrals

On October 22, 2026, Representative Sheri Biggs, a Republican from South Carolina's 3rd district, introduced three bills in the House. The three are HR 10859, the Biotech Defense Act; HR 10860, the Stop Beijing's Bots Act; and HR 10861, the Blocking Foreign Cellular Modules in Defense Systems Act of 2026. All three were introduced the same day, and all three were referred to the House Committee on Armed Services. m:…3288 m:…8862 m:…6841

The referrals are nearly identical, with one exception. The Biotech Defense Act was referred both to Armed Services and to the Permanent Select Committee on Intelligence — the only one of the three to draw the intelligence committee's attention. The other two went to Armed Services alone. m:…3288 m:…8862 m:…6841

What the record actually says about substance is limited. The legislative record states that HR 10861 aims to restrict the use of foreign cellular modules in defense systems. HR 10860's title names Beijing directly. The Biotech Defense Act's operative provisions are not described in the available record — only its title and its dual committee referral. m:…6841 m:…8862 m:…3288

The bill numbers tell their own small story: HR 10859, HR 10860, HR 10861 — consecutive numbers, which strongly suggests (this is inference, not a stated fact) the three were filed as a package, one after another. A legislator who files three related bills in sequence on the same day is building a portfolio, not reacting to news. And the subjects line up: biotechnology, automated accounts attributed to Beijing, and cellular modules in weapons systems. Whatever the text says, the titles stake out one theme — foreign technology in and around defense systems. m:…3288 m:…8862 m:…6841

A portfolio, not a coincidence

The most informative data point is the dual referral. When a bill goes to two committees, the House is saying the subject crosses jurisdictions — Armed Services handles the procurement side, Intelligence the threat side. That is how the referral system works in general, and it is the one piece of hard evidence about what the Biotech Defense Act is really about: its title says defense, its referral says the intelligence community gets a vote. m:…3288

This is analysis, not fact, but the shape of it is hard to miss: three introductions from one sponsor on one day, all filed together, all routed the same way, all circling the same target. Same-day, same-sponsor clusters like this are how a legislator plants a flag on a theme before the text is even public. The theme here is decoupling — foreign biotech suppliers, foreign cellular hardware, and foreign bot operations, each addressed in its own bill so each can move, or stall, on its own. m:…3288 m:…8862 m:…6841

What to watch

Introduction is only the first step, and most introduced bills never receive a markup. What matters for defense contractors and suppliers is the subject matter now named in introduced legislation: foreign cellular modules in defense systems are a stated target, Beijing's bots are named in a bill title, and a biotech bill has drawn the intelligence committee. If any of the three gets a hearing, the Biotech Defense Act's dual referral makes it the one to watch first — intelligence-committee involvement is the signal that a bill is being taken seriously as a security matter, not just a procurement one. m:…3288 m:…8862 m:…6841